Recent results from the UKCLL4 trial confirm the importance of determining molecular genetic markers in chronic lymphocytic leukaemia (CLL). 1 Patients with 17p deletion (420% of cells) were shown to have a complete response rate below 5% and a 100% progression rate within 3 years. 1 The poor prognosis is based on the complete inactivation of the tumour suppressor p53 (deletion of one allele and mutation of the remaining allele), which is of particular importance as most current therapies rely heavily on the use of chemotherapy requiring functional p53. 2 In the UKCLL4 trial, the cutoff value for 17p deletion was defined at 20%. Although it is clear that a deletion cutoff has to be defined, the hypothesis could be brought forward that more than the proportion of cells with the deletion, the status of the remaining allele may be crucial. We present two cases suggesting that 17p deletion even in a small fraction of cells is important, biologically and clinically.
In October 2002, a 63-year-old patient was diagnosed with CLL without a treatment indication at the time (Binet stage 
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Figure 1 Selection of pre-existing TP53 mutation and LOH after treatment with FC. DHPLC profiles of a control sample with wild-type p53 sequence, the initial CLL sample prior to therapy and at the time of FC/R-C-refractory disease. The percentage refers to the number of cells with a single signal of the p53 FISH probe corresponding to the cells with 17p deletion in percent. The x axis represents the elution time during DHPLC and the y axis the intensity of the absorbed signal in mV. The details of methods on PCR and DHPLC are shown in Supplementary Methods. (a) In the CLL sample prior to FC (before FC), a heterozygous polymorphism in intron 2 (double peak) is present. In the follow-up sample (after FC), LOH (loss of one peak) is observed corresponding to the emergence of a 17p deletion in the majority of cells. The control sample (WT) shows homozygosity of this polymorphism. In the pretherapeutic sample (before FC), a p53 mutation was found in a small proportion of cells as evidenced by the very small aberrant peak (n) (18 bp deletion in exon 7). This mutation could only be documented by sequencing after DHPLC purification of the mutant peak. In the follow-up sample (after FC), almost all CLL cells showed the mutation. The cells with wild-type p53 disappeared as evidenced by the loss of the wild-type allele (#). (b) Control sample (WT) with wild-type p53, initial CLL sample (before FC/ R-C) prior to immunochemotherapy and at the time of refractory disease (after FC/R-C). In the pretherapeutic sample, a TP53 mutation was found in a small proportion of cells as evidenced by the very small peak (n) (c.413C4T). In the sample after therapy, almost all CLL cells showed the mutation, suggesting that the clone with TP53 mutation was selected for during treatment with FC/R-C. See online version for colour figure. LOH, loss of heterozygosity; FC, fludarabine and cyclophosphamide; DHPLC, denaturing high-performance liquid chromatography; CLL, chronic lymphocytic leukaemia; R-C, rituximab plus cyclophosphamide; WT, wild type; FISH, fluorescence in situ hybridization. unavailable). In July 2004, he received four cycles of fludarabine and cyclophosphamide (FC) as first-line treatment (symptomatic lymphadenopathy). A 17p deletion in less than 20% of the cells was observed at this time. The patient did not respond to chemotherapy and received three cycles of rituximab (R) before being entered into a trial with subcutaneous alemtuzumab. At this time, 5 months after initial study, repeat analysis showed a 17p deletion in 77% of the cells. The patient died of pneumonia before the response could be assessed. Of note, the same TP53 mutation (18 bp in-frame deletion (p.I255fsn)) was found in both the pretherapeutic sample and in the sample obtained after resistance to FC. Denaturing high-performance liquid chromatography (DHPLC) profiles of a control sample with wild-type (WT) TP53 sequence, the initial CLL sample prior to FC and at the time of FC-refractory disease are shown in Figure 1a . The principle of DHPLC is based on separation of homo-and heteroduplex formation of individual PCR products at specific melting temperatures and set gradients. The primers, PCR and DHPLC conditions are available on request (Supplementary Methods). In the CLL sample prior to FC, a heterozygous polymorphism in intron 2 (double peak) is present. In the follow-up sample, loss of heterozygosity (loss of one peak) is observed corresponding to the emergence of a 17p deletion in the majority of cells. In the pretherapeutic sample, a TP53 mutation was found in a small proportion of cells as evidenced by the very small aberrant peak (n). This mutation could only be documented by sequencing after DHPLC purification of the mutant peak. In the follow-up sample (after FC), almost all CLL cells showed the mutation. Thus, the clone with TP53 mutation was selected for during treatment with chemotherapy. At the same time, the cells with wild-type TP53 responded to chemotherapy and disappeared as evidenced by the loss of the wild-type allele (#). In 2002, a 64-year-old patient was diagnosed with CLL (VH unmutated, ZAP70 neg., Binet B). When showing progressive disease, he was treated with FC in 2005. At this time, fluorescence in situ hybridization analysis showed a 17p deletion in 16% of the cells. After the first cycle, he developed a severe autoimmune haemolysis and the treatment was changed to rituximab plus cyclophosphamide (R-C, six cycles). He initially responded partial remission (PR), but 8 months after the termination of treatment he progressed and needed retreatment. At this time, repeat genetic analysis showed a 17p deletion in 495% of the cells. Mutational analysis of TP53 showed the same missense mutation (c.413C4T) present in both the pre-and post-therapeutic samples only at very different degrees (Figure 1b) . The DHPLC profiles are shown in Figure 1b (control sample with wild-type p53 WT, the initial CLL sample prior to immunochemotherapy and at the time of refractory disease). In the pretherapeutic sample, a TP53 mutation was found in a small proportion of cells as evidenced by the very small peak (n) (p.A138V; c.413C4T). In the sample after therapy, almost all CLL cells showed the mutation. Thus, the clone with TP53 mutation was selected for during treatment with R-C. Again the cells with wild-type TP53 responded to immunochemotherapy and disappeared as evidenced by the loss of the wild-type allele (#).
There is an ongoing debate if TP53 mutations are acquired events in CLL and some reports have suggested that the mutations may be caused by chemotherapy. 3, 4 The current report provides direct evidence for clonal selection of p53-deficient and chemotherapy-resistant cancer cells that exist prior to chemotherapy. The finding argues strongly for the use of non-genotoxic agents in tumours with p53 inactivation. [5] [6] [7] It also points to the importance of studying the TP53 status with a highly sensitive technique. Although the prognostic significance of mono-allelic TP53 alteration is currently unresolved, bi-allelic inactivation of TP53 will render the tumour cell highly resistant to classical chemotherapy, which should be avoided under these circumstances. Although the group of patients with 17p deletion is quite small in early stages and at first-line treatment, the detection of this chromosome aberration is of utmost importance because these patients are unlikely to respond to chemotherapy. There is a consensus that cytogenetics by fluorescence in situ hybridization should be obtained (at least for 17pÀ) in every patient before therapy is given. 8 For now, the 17pÀ abnormality is the first biological marker, which is incorporated in risk-stratified first-line treatment approaches in CLL (UK CAM-PRED study, CLL2O study). How far patients with TP53 mutations in the absence of 17p deletions would benefit from a similar non-genotoxic approach is currently unclear.
